Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (OACC) - Total Liabilities

Latest as of March 2026: $8.64 Million USD

Based on the latest financial reports, Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (OACC) has total liabilities worth $8.64 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See OACC current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share - Total Liabilities Trend (2024–2025)

This chart illustrates how Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see OACC total assets.

Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share Competitors by Total Liabilities

The table below lists competitors of Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share ranked by their total liabilities.

Company Country Total Liabilities
Limoneira Co
NASDAQ:LMNR
USA $130.12 Million
Azkoyen
MC:AZK
Spain €71.89 Million
SCI Pharmtech Inc
TW:4119
Taiwan NT$1.62 Billion
Celon Pharma SA
WAR:CLN
Poland zł141.95 Million
EMS Limited
NSE:EMSLIMITED
India Rs2.72 Billion
S H Kelkar and Company Limited
NSE:SHK
India Rs-13.62 Billion
Thayer Ventures Acquisition Corporation II Class A Ordinary Shares
NASDAQ:TVAI
USA $9.23 Million
Axiom Intelligence Acquisition Corp 1 Class A Ordinary Shares
NASDAQ:AXIN
USA $9.01 Million

Liability Composition Analysis (2024–2025)

This chart breaks down Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Oaktree Acquisition Corp. III Life Scien net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.87 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.04 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.04 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (2024–2025)

The table below shows the annual total liabilities of Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share from 2024 to 2025.

Year Total Liabilities Change
2025-12-31 $8.32 Million +7.39%
2024-12-31 $7.75 Million --

About Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share

NASDAQ:OACC USA Shell Companies
Market Cap
$213.26 Million
Market Cap Rank
#16404 Global
#3890 in USA
Share Price
$10.78
Change (1 day)
+0.00%
52-Week Range
$10.50 - $10.80
All Time High
$10.80
About

Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in … Read more